Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity

Pharmacogenetics and Genomics

Volumn 20, Issue 12, 2010, Pages 748-758

  Kim, Byung Soo ^a   Park, Se Min ^b   Uhm, Tae Gi ^a   Kang, Jin Hyun ^a   Park, Jong Sook ^c   Jang, An Soo ^c   Uh, Soo Taek ^c   Kim, Mi Kyeong ^d   Choi, Inseon S ^e   Cho, Sang Heon ^f   Hong, Cheon Soo ^g   Lee, Yong Won ^g   Lee, Jae Young ⁱ   Choi, Byoung Whui ^j   Park, Hae Sim ^b   Park, Byung Lae ^h   Shin, Hyoung Doo ^k,l   Chung, Il Yup ^a   Park, Choon Sik ^b,c  

^a Hanyang University   (South Korea)

^b Soonchunhyang University Bucheon Hospital   (South Korea)

^c Soonchunhyang University   (South Korea)

^d Chungbuk National University College of Medicine   (South Korea)

^e Chonnam National University Medical School   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Hallym University Medical Center   (South Korea)

ⁱ Chung Ang University   (South Korea)

^j Ajou University School of Medicine   (South Korea)

^k SNP Genetics Inc   (South Korea)

^l Sogang University   (South Korea)

more..

Author keywords

aspirin intolerant asthmatics; interleukin 4; polymorphism; promoter

Indexed keywords

ACETYLSALICYLIC ACID; CCAAT ENHANCER BINDING PROTEIN BETA; INTERLEUKIN 4; MESSENGER RNA; T LYMPHOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; FORCED EXPIRATORY VOLUME; GEL MOBILITY SHIFT ASSAY; GENOTYPE; HETEROZYGOSITY; HUMAN; INTRON; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78549267440     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283402155     Document Type: Article

References (51)

1. Samter M, Beers RF Jr. Concerning the nature of intolerance to aspirin. J Allergy 1967; 40:281-293.
2. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001; 87:177-180.
3. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-921.
4. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347:1493-1499.
5. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3:588-593.
6. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340:197-206.
7. Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med 2001; 52:1-14.
8. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242.
9. Dahlen SE, Malmstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9-14.
10. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265:956-959.
11. Perez GM, Melo M, Keegan AD, Zamorano J. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J Immunol 2002; 168:1428-1434.
12. Varga EM, Jacobson MR, Masuyama K, Rak S, Till SJ, Darby Y, et al. Inflammatory cell populations and cytokine mRNA expression in the nasal mucosa in aspirin-sensitive rhinitis. Eur Respir J 1999; 14:610-615.
13. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22:789-815.
14. The Collaborative Study on the Genetics of Asthma (CSGA). A genome-wide search for asthma susceptibility loci in ethnically diverse populations. Nat Genet 1997; 15:389-392.
15. Wiesch DG, Meyers DA, Bleecker ER. Genetics of asthma. J Allergy Clin Immunol 1999; 104:895-901.
16. Kauffmann F, Dizier MH, Annesi-Maesano I, Bousquet J, Charpin D, Demenais F, et al. EGEA (Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy) - descriptive characteristics. Clin Exp Allergy 1999; 29:17-21.
17. Basehore MJ, Howard TD, Lange LA, Moore WC, Hawkins GA, Marshik PL, et al. A comprehensive evaluation of IL4 variants in ethnically diverse populations: association of total serum IgE levels and asthma in white subjects. J Allergy Clin Immunol 2004; 114:80-87.
18. Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kawashima T, et al. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy 1998; 28:449-453. (Pubitemid 28215767)
19. Adjers K, Karjalainen J, Pessi T, Eklund C, Hurme M. Epistatic effect of TLR4 and IL4 genes on the risk of asthma in females. Int Arch Allergy Immunol 2005; 138:251-256.
20. Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klinnert M, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995; 25:74-78.
21. Suzuki I, Hizawa N, Yamaguchi E, Kawakami Y. Association between a C + 33T polymorphism in the IL-4 promoter region and total serum IgE levels. Clin Exp Allergy 2000; 30:1746-1749. (Pubitemid 32011754)
22. Walley AJ, Cookson WO. Investigation of an interleukin-4 promoter polymorphism for associations with asthma and atopy. J Med Genet 1996; 33:689-692.
23. Burchard EG, Silverman EK, Rosenwasser LJ, Borish L, Yandava C, Pillari A, et al. Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med 1999; 160:919-922.
24. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Bethesda, Maryland: National Institutes of Health National Heart, Lung and blood Institute; 2002.
25. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152:1107-1136.
26. Morris JF. Spirometry in the evaluation of pulmonary function. West J Med 1976; 125:110-118.
27. SensorMedics. Pulmonary utilities operator's manual: predicted normal equations. Yorba Linda, California: SensorMedics; 1988.
28. Cormican LJ, Farooque S, Altmann DR, Lee TH. Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity. Clin Exp Allergy 2005; 35:717-722.
29. Kim TH, Chang HS, Park SM, Nam BY, Park JS, Rhim T, et al. Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin Exp Allergy 2008; 38:1727-1737.
30. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques 2002; 32 (Suppl):56-58.
31. Hedrick PW. Gametic disequilibrium measures: proceed with caution. Genetics 1987; 117:331-341.
32. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
33. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74:765-769.
34. Klein SC, Golverdingen JG, van Wichen DF, Bouwens AG, Stuij I, Tilanus MG, et al. Expression of two interleukin 4 mRNA isoforms in B lymphoid cells. Cell Immunol 1996; 167:259-268.
35. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 1990; 9:1897-1906.
36. Davydov IV, Krammer PH, Li-Weber M. Nuclear factor-IL6 activates the human IL-4 promoter in T cells. J Immunol 1995; 155:5273-5279.
37. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Cell-type-specific activation of c-Jun N-terminal kinase by salicylates. J Cell Physiol 1999; 179:109-114.
38. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15:2057-2072.
39. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW. Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol 2004; 65:470-478.
40. Guo L, Urban JF, Zhu J, Paul WE. Elevating calcium in Th2 cells activates multiple pathways to induce IL-4 transcription and mRNA stabilization. J Immunol 2008; 181:3984-3993.
41. Li-Weber M, Krammer PH. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat Rev Immunol 2003; 3:534-543.
42. Gerli R, Paolucci C, Gresele P, Bistoni O, Fiorucci S, Muscat C, et al. Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. Blood 1998; 92:2389-2398.
43. Flescher E, Fossum D, Gray PJ, Fernandes G, Harper MJ, Talal N. Aspirin-like drugs prime human T cells. Modulation of intracellular calcium concentrations. J Immunol 1991; 146:2553-2559.
44. Crabtree GR, Clipstone NA. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 1994; 63:1045-1083.
45. Cianferoni A, Schroeder JT, Kim J, Schmidt JW, Lichtenstein LM, Georas SN, et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001; 97:1742-1749. (Pubitemid 32217242)
46. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997; 272:9962-9970.
47. Cieslik KA, Zhu Y, Shtivelband M, Wu KK. Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein beta activation and cyclooxygenase-2 expression by salicylate. J Biol Chem 2005; 280: 18411-18417.
48. Hebenstreit D, Giaisi M, Treiber MK, Zhang XB, Mi HF, Horejs-Hoeck J, et al. LEF-1 negatively controls interleukin-4 expression through a proximal promoter regulatory element. J Biol Chem 2008; 283: 22490-22497.
49. Nakashima H, Miyake K, Inoue Y, Shimizu S, Akahoshi M, Tanaka Y, et al. Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 2002; 3:107-109.
50. Berberich-Siebelt F, Klein-Hessling S, Hepping N, Santner-Nanan B, Lindemann D, Schimpl A, et al. C/EBPbeta enhances IL-4 but impairs IL-2 and IFN-gamma induction in T cells. Eur J Immunol 2000; 30:2576-2585.
51. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 2004; 5:389-396.